What is the mortality data for patients with Coronary Artery Disease (CAD) taking statins (HMG-CoA reductase inhibitors)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
DS

Dainyal Siddiqui, MD

Internal Medicine

MJ

Manuel Jimenez, MD

Cardiology

FP

Franz Pierre-Louis, MD

Infectious Disease

Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2025 • View editorial policy

From the Guidelines

Statin therapy is essential for patients with coronary artery disease (CAD) as it significantly reduces mortality and major vascular events. For patients with established CAD, high-intensity statins like atorvastatin 40-80mg daily or rosuvastatin 20-40mg daily should be used to reduce all-cause mortality and cardiovascular mortality 1. The benefits of high-intensity statin regimens include lowering LDL-C concentration by an average of ≥50%, which reduces major vascular events by approximately 15% in patients with CAD 1. Key points to consider when prescribing statins for CAD patients include:

  • High-intensity statin therapy should be used to achieve LDL-C targets below 70 mg/dL (or even below 55 mg/dL for very high-risk patients) 1
  • Treatment should be lifelong following CAD diagnosis
  • Regular monitoring of liver function tests and creatine kinase is recommended at baseline, 4-12 weeks after initiation, and annually thereafter
  • Statins work by inhibiting HMG-CoA reductase, reducing cholesterol synthesis in the liver, upregulating LDL receptors, and promoting plaque stabilization through anti-inflammatory effects
  • Beyond mortality benefits, statins also reduce non-fatal myocardial infarctions, strokes, and the need for coronary revascularization procedures in CAD patients 1.

From the FDA Drug Label

The risk reduction due to treatment with pravastatin on CHD mortality was consistent regardless of age Pravastatin significantly reduced the risk for total mortality (by reducing CHD death) and CHD events (CHD mortality or nonfatal MI) in patients who qualified with a history of either MI or hospitalization for unstable angina pectoris Table 7: LIPID - Primary and Secondary Endpoints Number (%) of Subjects Event Pravastatin 40 mg (N=4,512) Placebo (N=4,502) Risk Reduction p-value Primary Endpoint CHD mortality 287 (6.4) 373 (8.3) 24% 0.0004 Secondary Endpoints Total mortality 498 (11.0) 633 (14.1) 23% <0.0001 CHD mortality or nonfatal MI 557 (12.3) 715 (15.9) 24% <0. 0001 In the CARE study, the effect of pravastatin, 40 mg daily, on CHD death and nonfatal MI was assessed in 4,159 patients (3,583 men and 576 women) who had experienced a MI in the preceding 3 to 20 months Treatment with pravastatin significantly reduced the rate of first recurrent coronary events (either CHD death or nonfatal MI), the risk of undergoing revascularization procedures (PTCA, CABG), and the risk for stroke or TIA

Statin Mortality Data for Those with CAD:

  • Pravastatin significantly reduced the risk of CHD mortality by 24% in patients with a history of MI or hospitalization for unstable angina pectoris 2.
  • Pravastatin also reduced the risk of total mortality by 23% in these patients 2.
  • The risk reduction due to treatment with pravastatin was consistent across different age groups and regardless of sex 2.
  • Key benefits of pravastatin in patients with CAD include: + Reduced risk of CHD mortality + Reduced risk of total mortality + Reduced risk of nonfatal MI + Reduced risk of revascularization procedures (PTCA, CABG) + Reduced risk of stroke or TIA

From the Research

Statin Mortality Data for Those with CAD

  • The use of statins in patients with coronary artery disease (CAD) has been shown to reduce cardiovascular events and mortality 3, 4.
  • A study published in the American Journal of Cardiology found that patients with CAD who were discharged from the hospital with a statin prescription had a significantly reduced mortality rate at long-term follow-up compared to those who were not prescribed statins 4.
  • Another study published in the European Journal of Clinical Pharmacology found that high adherence to statin therapy was associated with a significant risk reduction of CAD, with a rate ratio of 0.82 compared to an adherence level of <20% 5.
  • A subgroup analysis of the REAL-CAD study found that renal dysfunction, poor glucose control, and high systolic blood pressure were significant nonlipid prognostic factors contributing to the incidence of cardiovascular events in statin-treated CAD patients 6.
  • High-intensity statins are recommended for patients with ASCVD, as well as high-risk patients without clinical ASCVD, with a goal of reducing low-density lipoprotein cholesterol by 50% or greater 7.

Key Findings

  • Statin therapy reduces cardiovascular events and mortality in patients with CAD 3, 4.
  • High adherence to statin therapy is associated with a significant risk reduction of CAD 5.
  • Nonlipid prognostic factors, such as renal dysfunction and poor glucose control, contribute to the incidence of cardiovascular events in statin-treated CAD patients 6.
  • High-intensity statins are recommended for high-risk patients, with a goal of reducing low-density lipoprotein cholesterol by 50% or greater 7.

Statin Therapy and Mortality

  • A study published in the American Journal of Cardiology found that patients with CAD who were discharged from the hospital with a statin prescription had a significantly reduced mortality rate at long-term follow-up, with a mortality rate of 5.7% compared to 11.7% for those who were not prescribed statins 4.
  • The REAL-CAD study found that renal dysfunction, poor glucose control, and high systolic blood pressure were significant predictors of mortality in statin-treated CAD patients 6.

References

Related Questions

What is the next recommendation for coronary management in a 56-year-old male with hyperlipidemia, obesity, and a history of cigarette smoking, who has moderate coronary artery calcifications on computed tomography (CT) scan of the lungs?
What additional management is recommended for a 67-year-old male with a history of anterior myocardial infarction (MI) 20 days ago, treated with percutaneous coronary intervention (PCI), aspirin (ASA), ticagrelor (Ticag), bisoprolol (2.5mg), ramipril (2.5mg), and empagliflozin (Jardiance, 10mg), with current normotension, normal pulse, and elevated low-density lipoprotein (LDL) levels, currently asymptomatic and on rosuvastatin (Crestor, 40mg)?
What is the first-line pharmacologic treatment for hyperlipidemia in a patient with moderate Atherosclerotic Cardiovascular Disease (ASCVD) risk?
What is the best management approach for a patient with an elevated LDL level of 127, HDL of 42, and an Agatston score of 28?
Should a patient with Hyperlipidemia (high cholesterol), specifically a Low-Density Lipoprotein (LDL) level of 170, High-Density Lipoprotein (HDL) of 40, and Hypertriglyceridemia (elevated triglycerides) of 250, and a Fasting Glucose level of 91, start statin therapy, and if so, what intensity, after 6 months of lifestyle modification?
Can strontium promote bone formation and increase bone density?
Why is methylphenidate (Ritalin) taken before breakfast?
What is Cyclopentolate (Cycloplegic agent)?
What is the diagnosis for a patient presenting with intermittent, non-painful pulsating sensations behind the ear, forearm, and left thigh?
What are the clinical presentation and diagnostic findings of a patient newly diagnosed with psoriatic arthritis upon admission?
What is the recommended duration to discontinue Plavix (clopidogrel) and Aspirin prior to dental procedures?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Ask a new Question. Chat with the Guidelines